文献速递前列腺癌

三联疗法联合机器人辅助减瘤性前列腺切除术治疗高瘤负荷转移性前列腺癌的多中心随机对照试验方案

Evaluation of triplet therapy combined with robot-assisted cytoreductive prostatectomy for high-volume metastatic prostate cancer: a multicentre randomised controlled trial protocol.
PubMed 文献 · BJU Int · 2026-08-14

本研究为开放标签、前瞻性、双臂、多中心随机对照试验,计划纳入88例18-75岁高瘤负荷转移性前列腺癌患者,随机1:1分为对照组(继续曲普瑞林+瑞维鲁胺)和试验组(加行机器人辅助减瘤性前列腺切除术)。主要终点为无进展生存期(PFS)和1年PFS率,次要终点为总生存期(OS)和健康相关生活质量(HRQoL)。

要点

  • 高瘤负荷mPCa患者经ADT+多西他赛+ARPI诱导后PSA≤0.2 ng/mL且适合手术者随机分组。
  • 试验组在标准三联疗法基础上加行机器人辅助减瘤性前列腺切除术。
  • 主要终点为PFS和1年PFS率,次要终点为OS和HRQoL。

核心结论

  • 三联疗法联合机器人辅助减瘤性前列腺切除术对高瘤负荷转移性前列腺癌的获益尚不明确,需随机对照试验验证。

研究设计与样本

  • 开放标签、前瞻性、双臂、多中心随机对照试验,计划纳入88例18-75岁高瘤负荷mPCa患者,1:1随机分组。

关键数值与推荐

  • 患者接受ADT(曲普瑞林15 mg每3个月)、4-6周期化疗(多西他赛75 mg/m2每3周)及ARPI(瑞维鲁胺240 mg每日一次)。
  • PSA≤0.2 ng/mL且判定适合手术者入组随机,对照组继续曲普瑞林+瑞维鲁胺,试验组加行机器人辅助减瘤性前列腺切除术。
  • 主要终点为PFS和1年PFS率,疾病进展定义为PSA进展、影像学进展或明确临床进展。
  • 次要终点包括OS和HRQoL,每3个月评估HRQoL,每6个月行影像学评估。

临床怎么用

  • 该方案为高瘤负荷mPCa患者在三联疗法基础上联合局部手术的前瞻性评估提供了标准化流程。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Prostate cancer (PCa) is the second most common cancer in men. For patients with high-volume metastatic PCa (mPCa) who are fit for docetaxel, a triplet therapy regimen consisting of androgen deprivation therapy (ADT), chemotherapy, and an androgen receptor pathway inhibitor (ARPI) is recommended. Adding local radiotherapy to triplet therapy has been shown to alleviate symptoms and reduce disease progression. However, the benefit of combining triplet therapy with local surgery remains unclear and warrants further investigation in the present study. STUDY DESIGN: This is an open-label, prospective, two-arm, multicentre, randomised controlled trial. ENDPOINTS: Primary endpoints are progression-free survival (PFS) and the 1-year PFS rate. Disease progression is defined as prostate-specific antigen (PSA) progression, radiological progression, or unequivocal clinical progression. Secondary endpoints include overall survival (OS) and health-related quality of life (HRQoL). PATIENTS AND METHODS: Patients aged 18-75 years with high-volume mPCa will receive ADT (triptorelin 15 mg every 3 months), four-six cycles of chemotherapy (docetaxel 75 mg/m2 every 3 weeks), and an ARPI (rezvilutamide 240 mg once daily). Patients achieving a PSA level ≤0.2 ng/mL and deemed suitable candidates for surgery will be enrolled. A total of 88 eligible patients will be randomised in a 1:1 ratio. The control group will continue treatment with triptorelin and rezvilutamide, while the experimental group will receive robot-assisted cytoreductive prostatectomy in addition to triptorelin and rezvilutamide. Baseline PSA levels will be recorded and re-examined at each chemotherapy cycle and every 3 months thereafter. Radiological evaluations will be performed every 6 months. Clinical progression will be assessed based on pain severity, performance status, and the need to initiate new anticancer therapy. HRQoL will be evaluated every 3 months. PFS and OS will be estimated using Kaplan-Meier curves and compared with the log-rank test. TRIAL REGISTRATION: Chinese Clinical Trial Registry: ChiCTR2600121819.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Yang X, He Z, Chen J, et al. Evaluation of triplet therapy combined with robot-assisted cytoreductive prostatectomy for high-volume metastatic prostate cancer: a multicentre randomised controlled trial protocol. BJU Int. 2026. PMID: 42598911. doi:10.1111/bju.70421

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。